SCHEMBL4868434

SCHEMBL4868434

Cc1nc(C)c(-c2ccc(-c3c(-c4ccccc4)c4sc(C(=O)O)cc4n3CC(=O)N3CCC(N4CCOCC4)CC3)cc2)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBX7 O95931 2/20 0.42
CDYL2 Q8N8U2 2/20 0.42
CDYL Q9Y232 2/20 0.42
CDY1; CDY1B Q9Y6F8 1/20 0.42
ACHE P22303 1/20 0.42
BRD4 O60885 1/20 0.41
CREBBP Q92793 1/20 0.41
TSHR P16473 2/20 0.39
ALDH1A1 P00352 2/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
CLK1 P49759 1/20 0.39
POLB P06746 2/20 0.39
GAA P10253 1/20 0.39
GRIN2B Q13224 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ACACB O00763 1/20 0.36
ACACA Q13085 1/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4872858 0.93 BRD4 (0.45) BRD4CREBBPTSHRALDH1A1RAB9A
SCHEMBL4874715 0.90 BRD4 (0.38) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4868424 0.88 CBX7 (0.38) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4877286 0.83 POLB (0.41) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL3931413 0.82 BRD4 (0.42) BRD4CREBBPTSHRALDH1A1RAB9A
SCHEMBL4872850 0.81 BRD4 (0.39) BRD4CREBBPTSHRALDH1A1RAB9A
SCHEMBL4877137 0.81 CBX7 (0.39) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL2996625 0.81 MAPK1 (0.48) BRD4CREBBPTSHRALDH1A1POLB
SCHEMBL2988735 0.81 MAPK1 (0.49) BRD4CREBBPALDH1A1POLBGRIN2B
SCHEMBL4877781 0.80 ACHE (0.43) CBX7CDYL2CDYLCDY1; CDY1BACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 CBX7 2500/4885CDYL2 4283/4885CDYL 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.